Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study suggests. Peripheral arterial disease is a difficult-to-treat problem ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic o ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

According to national statistics, nearly a quarter of U.S. adults ages 75 and older have heart disease, an umbrella term for a cluster of heart conditions, including coronary artery disease and heart ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...